Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 10% - Octapharma

Drug Profile

Immune globulin 10% - Octapharma

Alternative Names: 10% high purity immunoglobulin; 10% IVIG; NewGam; octagam 10%; Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation; Panzyga

Latest Information Update: 16 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Dermatomyositis
  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Aug 2017 Phase-III clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy in USA, Australia, Czech Republic, Hungary, Romania (IV) (NCT02638207)
  • 17 May 2017 Immune globulin 10% - Octapharma receives Orphan Drug status for Dermatomyositis in USA
  • 27 Feb 2017 Phase-III clinical trials in Dermatomyositis (Treatment-experienced) in USA, Czech Republic, Germany, Hungary (IV) (NCT02728752)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top